Biosimilar Antibodies

Tilogotamab is an enhanced agonistic formulation composed of two antibodies, each targeting distinct epitopes on death receptor type 5 (DR5). This specific interaction with DR5 facilitates its activation, making Tilogotamab a valuable tool in the study of multiple myeloma (MM). This product is designed for research use, focusing on elucidating the pathways and mechanisms associated with DR5 in multiple myeloma.

Zagotenemab (LY3303560) is a humanized monoclonal antibody designed to selectively bind to and neutralize tau protein deposits in the brain. This antibody is specifically developed for use in research related to Alzheimer's disease, providing a critical tool for investigating the role of tau in neurodegeneration and assessing potential therapeutic strategies.

The Anti-GREM1/Gremlin Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target GREM1/Gremlin, a key regulatory protein involved in embryonic development and various pathological processes. This antibody features a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control purposes, researchers should use the Human IgG4 kappa, Isotype Control, to ensure specificity and accuracy in their experimental results. This product is ideal for use in a range of biochemical assays where GREM1/Gremlin detection and inhibition are required.

Zuberitamab (HS006) is a monoclonal antibody specifically designed to target CD20, a cell surface protein predominantly expressed on B cells. This antibody is utilized extensively in the study of various B-cell malignancies, including diffuse large B-cell lymphoma. Zuberitamab serves as a critical tool in oncological research, aiding in the elucidation of CD20's role in cancer pathogenesis and the development of targeted therapies.

Enapotamab is a reference antibody targeting AXL/UFO, which is instrumental in synthesizing Bcl-xl inhibitor antibody-drug conjugates. This antibody serves as a critical tool in the development of targeted therapies, facilitating research into novel cancer treatment modalities.

Lomvastomig is a human IgG1 κ monoclonal antibody targeting PDCD1 and HAVCR2. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

FG-3246 (FOR46) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CD46. This antibody is comprised of a human IgG1 heavy chain and a human lambda light chain, with a predicted molecular weight of 143.6 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa. This product is pivotal for research focused on immune response modulation and cellular regulation mediated by CD46.

Anti-Siglec-2 / CD22 (NCI m971) is a humanized monoclonal antibody specifically designed to target CD22, a member of the Siglec family of lectins predominantly expressed on B cells. This antibody is utilized in the therapeutic management of acute lymphoblastic leukemia (ALL), offering a targeted approach to treatment by binding to the CD22 antigen, thereby modulating immune response and B cell activity.

Luvagrobart is a human IgG1 κ monoclonal antibody targeting nerve growth factor (NGF). For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

Tamtuvetmab (AT-005) is a caninized version of blontuvetmab targeting CD52, designed specifically for veterinary use. This therapeutic antibody has demonstrated an ability to increase progression-free survival (PFS) and shows in vivo efficacy in canine subjects with naive T-cell lymphoma (LSA). Tamtuvetmab has received approval for veterinary applications, underscoring its relevance and utility in the treatment of lymphoma in dogs.

Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody designed to function as an immunomodulator by targeting and binding to the epidermal growth factor-like domain 7 (EGFL7). This antibody selectively inhibits the interaction between EGFL7 and endothelial cells, which may impede vascular regrowth and modulate the effects of vascular endothelial growth factor (VEGF) inhibition. Parsatuzumab is primarily researched for its potential applications in the regulation of angiogenesis and tumor microenvironment modulation.

Naxitamab (Hu3F8) is a humanized monoclonal antibody specifically designed to target the disialoganglioside GD2, a glycolipid antigen predominantly expressed on the surface of neuroblastoma, osteosarcoma, and other GD2-positive cancer cells. This antibody is utilized extensively in the research of these cancers, providing a critical tool for studying tumor behavior, progression, and potential therapeutic interventions.

The Anti-DSG3 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target Desmoglein 3 (DSG3). This antibody comprises a human IgG1 type heavy chain and a human kappa light chain, with a predicted molecular weight of 146.54 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a range of research applications, focusing on the study of DSG3's role in cellular adhesion and its implications in autoimmune diseases such as pemphigus vulgaris.

Bemarituzumab (FUT8-KO) is a monoclonal antibody targeting FGFR2b, expressed in CHO cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). This genetic modification leads to the absence of core fucose in the polysaccharide structure of the Fc domain, significantly enhancing the antibody's antibody-dependent cellular cytotoxicity (ADCC). The lack of fucose results in increased affinity for human FcγRIIIa, potentially improving therapeutic efficacy. Bemarituzumab (FUT8-KO) is designed for advanced research applications focusing on cancer therapy and the study of FGFR2b-related biological pathways.

Bocunebart is a humanized monoclonal antibody designed to target human ADCYAP1, also known as adenylate cyclase-activating polypeptide (PACAP). By specifically binding to ADCYAP1, Bocunebart effectively inhibits the associated inflammatory signaling pathways, exhibiting potent anti-inflammatory activity. This antibody is particularly valuable for research focused on inflammation-related diseases, offering significant insights into the modulation of inflammatory responses.

The Anti-SLAMF6 Antibody (h20F3ec), also known as SGN-CD352A antibody, is a recombinant human antibody expressed in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets SLAMF6/CD352, a cell surface protein involved in the regulation of immune cell interactions. The Anti-SLAMF6 Antibody (h20F3ec) comprises a muIgG1 type heavy chain and a huκ type light chain, and exhibits a predicted molecular weight of 145.9 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended as the isotype control for this antibody. This product is essential for research focused on immune regulation and the SLAM family signaling pathways.

Tregalizumab is a humanized IgG1 monoclonal antibody targeting the CD4 antigen. It selectively enhances the suppressive function of regulatory T cells (Tregs) in vitro, making it a valuable tool for studying autoimmune disorders and allergies where Treg activity is compromised. This antibody's specificity and mechanism of action provide a critical resource for investigating the pathophysiology of immune tolerance and its therapeutic modulation.

Picankibart is a monoclonal antibody of the IgG1κ subtype, derived from mouse sources, specifically designed to target IL23A. This antibody is engineered for high specificity and affinity towards the interleukin-23 alpha subunit, making it an essential tool for research focused on inflammatory pathways and immune response regulation.

Tobemstomig is a humanized IgG1 κ monoclonal antibody that targets both PDCD1 and LAG3. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This dual specificity enhances its potential for research into immune checkpoint pathways and their role in immunotherapy.

Itanistomig is a bispecific antibody designed to target CD274 and CD47. Structurally characterized as VH-G1CH1-h-H-γ1_L-κ-L-κ, this antibody facilitates dual engagement with these critical immune checkpoint proteins, enhancing the potential for immune system modulation in therapeutic applications. Itanistomig is engineered for high specificity and affinity, making it a valuable tool in research focused on cancer immunotherapy and immune regulation.

The Anti-OX2R/CD200R1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the OX2R/CD200R1 receptor. This antibody has a predicted molecular weight of 146.58 kDa. For isotype control, reference is made to the Human IgG4 kappa, Isotype Control, ensuring accurate assessment of antibody specificity and performance in various assays.

Tabalumab (LY2127399) is a human monoclonal antibody of the IgG4 subtype designed to specifically target and neutralize both membrane-bound and soluble forms of B-cell activating factor (BAFF). This antibody exhibits potent neutralizing activity, making it a valuable tool for research into autoimmune disorders including rheumatoid arthritis, renal failure, and systemic lupus erythematosus. Tabalumab's specificity and efficacy in modulating BAFF-mediated processes provide a critical resource for investigating the pathophysiology and potential therapeutic interventions for these conditions.

NGM-438 is a humanized IgG1 monoclonal antibody that specifically targets LAIR1. This antibody has demonstrated efficacy in reversing collagen-induced immune suppression in myeloid cells. Additionally, NGM-438 enhances anti-PD1 monoclonal antibody-driven T cell responses, as evidenced in various immune cell-based functional assays. This product is pivotal for research focused on immunomodulation and the investigation of immune checkpoint pathways.

The Anti-beta Amyloid Antibody DLX212 specifically targets the beta-amyloid protein, which is a principal constituent of the amyloid plaques characteristic of Alzheimer’s disease pathology. This antibody is designed for use in research focused on the detection, quantification, and characterization of beta-amyloid aggregates in neurological studies.

The Anti-SCN11a/Nav1.9 Antibody is a human monoclonal antibody produced in CHO cells, specifically targeting the SCN11a/Nav1.9 channel. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 143.94 kDa. For experimental controls, the recommended isotype control is Human IgG1 kappa. This product is essential for research focusing on the role of the SCN11a/Nav1.9 channel in neurological functions and disorders.

Libevitug is a human monoclonal antibody of the IgG1λ2 subtype designed to target Hepatitis B virus (HBV). For accurate experimental control, it is recommended to use Human IgG1 lambda2 as an isotype control.

Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody designed to specifically target the spike glycoprotein of SARS-CoV-2. This antibody exhibits high affinity binding to the receptor-binding domain (RBD) of the recombinant spike protein, demonstrated by an equilibrium dissociation constant (Kd) of 0.21 nM and an effective concentration (EC50) of 14.9 ng/mL. These properties suggest that Beludavimab is highly effective in binding to the spike protein, potentially inhibiting the virus's ability to enter host cells and proliferate. This antibody is a valuable tool for research focused on the mechanisms of SARS-CoV-2 infection and the development of therapeutic strategies.

Obinutuzumab (GA101) is a humanized IgG1 monoclonal antibody of Type II targeting CD20, currently under development for the treatment of non-Hodgkin lymphoma. This therapeutic antibody is designed to bind specifically to the CD20 antigen expressed on the surface of B cells, facilitating targeted immunotherapy with potential applications in oncological research and clinical practice.

The Anti-CEACAM1/3/5/6/8 Antibody (6G5j) is a chimeric mouse monoclonal antibody of the IgG1 κ isotype, designed to target human CEACAM1, CEACAM3, CEACAM5, CEACAM6, and CEACAM8. This antibody enables precise identification and quantification of these carcinoembryonic antigen-related cell adhesion molecules, which are significant in various cellular processes including angiogenesis, apoptosis, and cell signaling. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control in conjunction with this antibody.

Vepsitamab (AMG 199) is a bispecific T-cell engager (BiTE) antibody designed for precise dual targeting of CD3 on T cells and MUC17 on tumor cells. This antibody facilitates the redirection of T cell cytotoxic activity towards MUC17-expressing tumor cells, resulting in targeted tumor cell lysis. Additionally, Vepsitamab promotes T cell activation and proliferation, enhancing anti-tumor immune responses. This product is pivotal for research focused on cancer immunotherapy and the molecular mechanisms of T cell-mediated cytotoxicity.

Spesolimab (BI 655130) is a humanized IgG1κ monoclonal antibody derived from mouse sources, targeting the interleukin-36 receptor (IL-36R). IL-36 is critical in mediating immune responses, and Spesolimab has shown potential efficacy in clinical studies for the treatment of palmoplantar pustulosis (PPP). The therapeutic action of Spesolimab includes the modulation of biomarkers linked to innate immunity and Th1/Th17 and neutrophil pathways, suggesting its role in altering inflammatory processes. This antibody is currently under investigation for its therapeutic potential and mechanism of action in immune-mediated dermatological conditions.

NGM-313 is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically targeting Klotho Beta. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.

Keliximab (SB-210396) is a chimeric human/macaque IgG1 monoclonal antibody targeting CD4 with a dissociation constant (Ki) of 1.0 nM for soluble CD4. This antibody effectively blocks T-cell proliferation and inhibits the production of interleukin-2 (IL-2), mechanisms critical in the immune response. Due to its specific action on T-cells, Keliximab is extensively utilized in oncological research to study the modulation of the immune system in the tumor microenvironment.

LK-1 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target S100A4, a protein implicated in various pathological processes including tumor progression and metastasis. This antibody is comprised of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa, Isotype Control.

The Anti-RAMP3 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the Receptor Activity-Modifying Protein 3 (RAMP3). This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody serves as a crucial tool for the study of receptor function and signaling pathways associated with RAMP3.

Pozelimab (REGN3918) is a fully humanized IgG4 monoclonal antibody specifically developed to target and bind with high affinity to complement component 5 (C5) and its variants. This antibody effectively inhibits the cleavage of C5, thereby blocking complement-mediated hemolysis. It is an essential tool for investigating the pathophysiology of complement-mediated disorders and is suitable for use in various research settings focused on these diseases.

The Anti-CAPRIN1 Antibody is a humanized monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target CAPRIN1 (Cell Cycle Associated Protein 1). This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, exhibiting a predicted molecular weight of approximately 150 kDa. For isotype control purposes, researchers should use the Human IgG1 kappa, Isotype Control, to ensure specificity and accuracy in their experimental outcomes. This product is essential for studies focusing on the role of CAPRIN1 in cell cycle regulation and its potential implications in various cellular processes and diseases.

Loncastuximab (RB4v1.2) is a monoclonal antibody targeting CD19, demonstrating significant antitumor activity. This antibody is primarily utilized in the investigation of hematological malignancies, including Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Its specificity for CD19 makes it a valuable tool for researchers studying the pathophysiology and potential therapeutic interventions for these conditions.

Lampalizumab (RG 7417) is a humanized monoclonal antibody designed to selectively target complement Factor D within the alternative complement pathway. By binding to an exosite, Lampalizumab effectively inhibits the access of Factor B to the active site, thereby modulating the pathway's activity. This antibody is primarily utilized in the study of age-related macular degeneration (AMD), providing a valuable tool for researchers exploring the pathophysiology and potential therapeutic interventions for this condition.

The Anti-ENPP3/CD203c Antibody (AGS-16C3F antibody) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3), also known as CD203c. This antibody comprises a human immunoglobulin G2 (huIgG2) heavy chain and a human kappa (huκ) light chain, and has a predicted molecular weight of 154.04 kDa. For use as a negative control in experiments, the Human IgG2 kappa, Isotype Control is recommended. This antibody is essential for research focused on allergic responses, mast cell activation, and other immunological functions mediated by ENPP3/CD203c.

Lemzoparlimab (TJ011133; TJC4) is a humanized IgG4 monoclonal antibody targeting CD47. This antibody exhibits potent antitumor activity, making it a valuable tool for research in cancer immunotherapy. Lemzoparlimab functions by engaging with the CD47 protein, a key regulator in the 'don't eat me' signal that protects cancer cells from macrophage-mediated phagocytosis. By blocking this signal, Lemzoparlimab promotes the phagocytosis of malignant cells, thereby facilitating an immune response against the tumor. This mechanism highlights its potential utility in studies focused on tumor immunity and therapeutic antibody development.

The Anti-CD47 Antibody (B6.H12) is a mouse monoclonal IgG1, κ antibody engineered to target human CD47. This antibody is designed for specificity to CD47, a critical regulator in the 'don't eat me' signal which inhibits phagocytosis, making it a vital tool in cancer immunotherapy research. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control in conjunction with this antibody to ensure specificity and consistency in results.

Licaminlimab (OCS-02) is a single-chain antibody fragment specifically targeting TNF alpha, a pro-inflammatory cytokine predominantly secreted by macrophages and monocytes. This monoclonal antibody fragment is designed to neutralize TNF alpha, thereby modulating inflammatory responses. It is applicable in research focused on the pathophysiology and treatment of diseases characterized by excessive inflammation.

Dibotatug is a human monoclonal antibody of the IgG1κ subtype that specifically targets KLRD1. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Imelciment is a human monoclonal antibody of the half-IgG4 subtype, featuring a kappa light chain and engineered hinge regions (h-CH2-CH3). Specifically designed to target NPR1 (Natriuretic Peptide Receptor 1), this antibody is optimized for high specificity and stability, making it a valuable tool for research into cardiovascular signaling pathways and potential therapeutic applications.

The Anti-CD34 Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the CD34 antigen. This antibody is comprised of a human IgG2 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For isotype control, the Human IgG1 kappa Isotype Control is recommended as a reference standard. This product is essential for research focused on hematopoietic stem cells and vascular biology, providing a critical tool for both basic research and clinical studies.

Rezetamig is a monoclonal antibody that targets both CD3E and CD22 molecules. This dual specificity allows for enhanced targeting of immune cells, making it a valuable tool in immunological research and therapeutic applications.